Remove tag funding
article thumbnail

STAT+: Pharmalittle: Some employers cut insurance coverage for weight loss drugs; U.S. urges ADHD pill makers to boost production

STAT

The outlays are straining the finances of some plans, including those funded by employers. The Besides the $26,500 annual price tag, treatment could cost U.S.  The reimbursement cuts, along with restrictions that other employers are implementing, mark the financial downside of the drugs’ medical triumph.

article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

Growing R&D funding and research activity, higher product availability and lower outsourcing costs are likely to drive market growth. Tag Copenhagen A/S (Denmark). The research noted that the oligonucleotide synthesis market in the Asia-Pacific region is expected to develop at the quickest rate during the forecast period.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Amylyx ALS drug draws criticism over $158,000 price tag

pharmaphorum

Most patients are only now being enrolled in Europe, according to co-chief executive officers of Amylyx Justin Klee and Joshua Cohen, who say they arrived at the price following discussions with patients, as well as insurers and other stakeholders, but also mindful of future funding of research. ALS affects over 30,000 people in the US.

article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

million price tag make it is the most expensive treatment ever approved for NHS funding. Zolgensma meanwhile has been recommended for some babies aged up to 2 months with type 1 SMA and for treating pre-symptomatic SMA, even though the gene therapy’s £1.79

98
article thumbnail

Second unanimous FDA adcomm vote boosts bluebird bio

pharmaphorum

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 million for each one-shot therapy, but bluebird decided to take it off the market and exit the EU market altogether, blaming reluctance by payers to fund treatment. Eli-cel was also previously approved in Europe as Skysona.

FDA 59
article thumbnail

New purification method could enhance protein drug manufacturing

European Pharmaceutical Review

The authors explained that these are commonly used for tagging proteins for study or attaching protein drugs to drug-delivering nanoparticles. In addition to the Gates Foundation, the research was partly funded by a National Science Foundation Graduate Research Fellowship.

article thumbnail

NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group

pharmaphorum

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. “NICE’s initial ‘no’ to approving risdiplam for NHS funding is not unexpected,” said SMA UK this morning.